EMEA-000181-PIP02-13-M01 - paediatric investigation plan

Cannabidiol

delta-9-tetrahydrocannabinol

Key facts

• Invented name:
  Sativex
• Active Substance:
  • Cannabidiol
  • delta-9-tetrahydrocannabinol
• Therapeutic area:
  Pain
• Decision number:
  P/0373/2022
• PIP number:
  EMEA-000181-PIP02-13-M01
• Pharmaceutical form(s):
  Oromucosal spray
• Condition(s) / indication(s):
  Treatment of pain
• Route(s) of administration:
  Oromucosal use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  09/09/2022

Decision

P/0373/2022 : EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for cannabidiol / delta-9- tetrahydrocannabinol (Sativex), (EMEA-000181-PIP02-13-M01)

AdoptedReference Number: EMA/705362/2022